Anal squamous cell carcinoma: are we improving outcomes?

Alicia Mackowski, Michael Levitt, Gregory Makin, Paul Salama, Patrick Tan, Cheryl Penter, Cameron Platell

Research output: Contribution to journalArticle

Abstract

Background: Anal squamous cell carcinoma (SCC) is a rare malignancy. The purpose of this study was to review a single institution's experience. Methods: All patients with anal SCC from St John of God Subiaco Hospital database were identified over a 10-year period (2006–2016). Patients with stage 1 anal verge tumours underwent wide local excision, all remaining patients were offered chemoradiation (CRT) as an initial treatment modality (a fluorouracil-based regimen in conjunction with mitomycin). Outcomes included recurrence, overall survival and survival following salvage surgery. Results: Forty-seven patients were identified. Median age was 60 years and median follow-up was 2.73 years. Five-year rates of recurrence and overall survival were 35.8% (95% confidence interval (CI) 23.2–52.4%) and 65.4% (95% CI 47.0–78.7%), respectively. Locoregional failure occurred most commonly at the primary site. Eight patients underwent salvage abdominoperineal resection for persistent or recurrent disease, and four of these patients died within 5 years. Conclusion: CRT is a proven and reasonable effective approach in managing anal cancer. Observed recurrence and overall survival rates in this study resemble the published data. Despite newer methods of treatment being investigated, the treatment for anal SCC has not significantly changed in the past four decades and novel approaches are needed to further improve outcomes.

Original languageEnglish
Pages (from-to)1013-1016
Number of pages4
JournalANZ Journal of Surgery
Volume88
Issue number10
DOIs
Publication statusPublished - 1 Oct 2018

Fingerprint

Squamous Cell Carcinoma
Recurrence
Survival
Psychosexual Development
Confidence Intervals
Anus Neoplasms
Mitomycin
Fluorouracil
Neoplasms
Therapeutics
Survival Rate
Databases

Cite this

Mackowski, A., Levitt, M., Makin, G., Salama, P., Tan, P., Penter, C., & Platell, C. (2018). Anal squamous cell carcinoma: are we improving outcomes? ANZ Journal of Surgery, 88(10), 1013-1016. https://doi.org/10.1111/ans.14745
Mackowski, Alicia ; Levitt, Michael ; Makin, Gregory ; Salama, Paul ; Tan, Patrick ; Penter, Cheryl ; Platell, Cameron. / Anal squamous cell carcinoma : are we improving outcomes?. In: ANZ Journal of Surgery. 2018 ; Vol. 88, No. 10. pp. 1013-1016.
@article{aa4f763bf6614a179fd47c68d0232cfa,
title = "Anal squamous cell carcinoma: are we improving outcomes?",
abstract = "Background: Anal squamous cell carcinoma (SCC) is a rare malignancy. The purpose of this study was to review a single institution's experience. Methods: All patients with anal SCC from St John of God Subiaco Hospital database were identified over a 10-year period (2006–2016). Patients with stage 1 anal verge tumours underwent wide local excision, all remaining patients were offered chemoradiation (CRT) as an initial treatment modality (a fluorouracil-based regimen in conjunction with mitomycin). Outcomes included recurrence, overall survival and survival following salvage surgery. Results: Forty-seven patients were identified. Median age was 60 years and median follow-up was 2.73 years. Five-year rates of recurrence and overall survival were 35.8{\%} (95{\%} confidence interval (CI) 23.2–52.4{\%}) and 65.4{\%} (95{\%} CI 47.0–78.7{\%}), respectively. Locoregional failure occurred most commonly at the primary site. Eight patients underwent salvage abdominoperineal resection for persistent or recurrent disease, and four of these patients died within 5 years. Conclusion: CRT is a proven and reasonable effective approach in managing anal cancer. Observed recurrence and overall survival rates in this study resemble the published data. Despite newer methods of treatment being investigated, the treatment for anal SCC has not significantly changed in the past four decades and novel approaches are needed to further improve outcomes.",
keywords = "anal cancer, recurrence, squamous cell carcinoma, survival",
author = "Alicia Mackowski and Michael Levitt and Gregory Makin and Paul Salama and Patrick Tan and Cheryl Penter and Cameron Platell",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/ans.14745",
language = "English",
volume = "88",
pages = "1013--1016",
journal = "Australian New Zealand Journal of Surgery",
issn = "1445-1433",
publisher = "John Wiley & Sons",
number = "10",

}

Mackowski, A, Levitt, M, Makin, G, Salama, P, Tan, P, Penter, C & Platell, C 2018, 'Anal squamous cell carcinoma: are we improving outcomes?' ANZ Journal of Surgery, vol. 88, no. 10, pp. 1013-1016. https://doi.org/10.1111/ans.14745

Anal squamous cell carcinoma : are we improving outcomes? / Mackowski, Alicia; Levitt, Michael; Makin, Gregory; Salama, Paul; Tan, Patrick; Penter, Cheryl; Platell, Cameron.

In: ANZ Journal of Surgery, Vol. 88, No. 10, 01.10.2018, p. 1013-1016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anal squamous cell carcinoma

T2 - are we improving outcomes?

AU - Mackowski, Alicia

AU - Levitt, Michael

AU - Makin, Gregory

AU - Salama, Paul

AU - Tan, Patrick

AU - Penter, Cheryl

AU - Platell, Cameron

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Anal squamous cell carcinoma (SCC) is a rare malignancy. The purpose of this study was to review a single institution's experience. Methods: All patients with anal SCC from St John of God Subiaco Hospital database were identified over a 10-year period (2006–2016). Patients with stage 1 anal verge tumours underwent wide local excision, all remaining patients were offered chemoradiation (CRT) as an initial treatment modality (a fluorouracil-based regimen in conjunction with mitomycin). Outcomes included recurrence, overall survival and survival following salvage surgery. Results: Forty-seven patients were identified. Median age was 60 years and median follow-up was 2.73 years. Five-year rates of recurrence and overall survival were 35.8% (95% confidence interval (CI) 23.2–52.4%) and 65.4% (95% CI 47.0–78.7%), respectively. Locoregional failure occurred most commonly at the primary site. Eight patients underwent salvage abdominoperineal resection for persistent or recurrent disease, and four of these patients died within 5 years. Conclusion: CRT is a proven and reasonable effective approach in managing anal cancer. Observed recurrence and overall survival rates in this study resemble the published data. Despite newer methods of treatment being investigated, the treatment for anal SCC has not significantly changed in the past four decades and novel approaches are needed to further improve outcomes.

AB - Background: Anal squamous cell carcinoma (SCC) is a rare malignancy. The purpose of this study was to review a single institution's experience. Methods: All patients with anal SCC from St John of God Subiaco Hospital database were identified over a 10-year period (2006–2016). Patients with stage 1 anal verge tumours underwent wide local excision, all remaining patients were offered chemoradiation (CRT) as an initial treatment modality (a fluorouracil-based regimen in conjunction with mitomycin). Outcomes included recurrence, overall survival and survival following salvage surgery. Results: Forty-seven patients were identified. Median age was 60 years and median follow-up was 2.73 years. Five-year rates of recurrence and overall survival were 35.8% (95% confidence interval (CI) 23.2–52.4%) and 65.4% (95% CI 47.0–78.7%), respectively. Locoregional failure occurred most commonly at the primary site. Eight patients underwent salvage abdominoperineal resection for persistent or recurrent disease, and four of these patients died within 5 years. Conclusion: CRT is a proven and reasonable effective approach in managing anal cancer. Observed recurrence and overall survival rates in this study resemble the published data. Despite newer methods of treatment being investigated, the treatment for anal SCC has not significantly changed in the past four decades and novel approaches are needed to further improve outcomes.

KW - anal cancer

KW - recurrence

KW - squamous cell carcinoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85052819528&partnerID=8YFLogxK

U2 - 10.1111/ans.14745

DO - 10.1111/ans.14745

M3 - Article

VL - 88

SP - 1013

EP - 1016

JO - Australian New Zealand Journal of Surgery

JF - Australian New Zealand Journal of Surgery

SN - 1445-1433

IS - 10

ER -

Mackowski A, Levitt M, Makin G, Salama P, Tan P, Penter C et al. Anal squamous cell carcinoma: are we improving outcomes? ANZ Journal of Surgery. 2018 Oct 1;88(10):1013-1016. https://doi.org/10.1111/ans.14745